Hydrocodone Combination Product Rescheduling: The Bigger Picture

Published Online: Friday, January 31, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II will not make the medications safer for patients. Instead, he argues, there should be more education for those who prescribe the medications and pharmacists who dispense them.
 
This is the last in a series of 12 videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Prescription opioid dispensing and overdoses decreased after abuse-deterrent oxycodone hit the market and propoxyphene left it.
Deaths related to oxycodone overdose dropped 25% in Florida after the state adopted a Prescription Drug Monitoring Program to track controlled substance dispensing.
Often considered a consequence of the mother’s illegal drug use, drug withdrawal in babies may also be linked to legally obtained narcotics.
The FDA has outlined the type of studies opioids need to complete to win approval for abuse-deterrence.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$